Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | ACMSD | Q8TDX5 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | HSD17B14 | Q9BPX1 | 1/20 | 0.32 |
| ▸ | LMNA | P02545 | 2/20 | 0.32 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.32 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6673583 | 0.89 | KDM4E (0.46) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL13793158 | 0.89 | KDM4E (0.46) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL21615647 | 0.80 | KDM4E (0.44) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL28244305 | 0.78 | KDM4E (0.48) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL14346588 | 0.78 | KDM4E (0.48) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL13274037 | 0.76 | P2RX7 (0.50) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL8281251 | 0.76 | P2RX7 (0.50) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL29741163 | 0.75 | KDM4E (0.45) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL23226820 | 0.74 | NOS2 (0.46) | KDM4EALOX15TSHRACMSDTDP1 | |
| SCHEMBL21264073 | 0.74 | GRM5 (0.44) | KDM4EALOX15TSHRACMSDTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20190256650-A1 | CATALYTIC CARBONYLATION CATALYSTS AND METHODS | NOVOMER, INC. (US) | 2019-08-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190256650-A1 | CATALYTIC CARBONYLATION CATALYSTS AND METHODS | CBR3, CBR1, EPHX2 | KDM4E 448/4885ALOX15 542/4885TSHR 4642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.